The Israel Institute for Biological Research (IIBR) is leading the Israeli applicative research in a response to the COVID-19 outbreak. As a main goal, IIBR is making advanced R&D efforts in developing the vaccine based on an engineered virus and monoclonal neutralizing antibodies treatment for SARS-Cov-2 virus. These vaccine and therapeutic antibodies will provide a state of the art protection for the Israeli population. At the same time, IIBR is performing “Corona” R&D in different aspects of biological safety and protective issues, complex diagnostic and risk assessment.
IIBR’s contribution is well appreciated among the international scientific community and decision makers.